Clinical Trials
22 trialsNCT01589861 2026-04-21
PIKHER2
Institut Paoli-Calmettes
Phase 1/2 Terminated
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01576666 2020-12-19
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02154776 2020-12-19
LeeBLet
Novartis
Phase 1 Completed
NCT02088684 2020-12-17
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT01626209 2020-12-09
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01068483 2020-12-08
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01610284 2020-08-25
BELLE-2
Novartis
Phase 3 Completed
NCT01816594 2019-11-14
NeoPHOEBE
Novartis
Phase 2 Completed
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT01790932 2019-01-23
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01923168 2018-09-14
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Novartis
Phase 2 Completed
NCT02404844 2018-04-20
PIKTAM
University Hospital, Essen
Phase 2 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT01339442 2017-01-25
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Washington University School of Medicine
Phase 1 Completed
NCT01132664 2016-08-17
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Novartis
Phase 1/2 Terminated
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01501604 2015-09-17
BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01953445 2014-12-08
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01513356 2014-04-02
Pharmacodynamic Study of BKM120 in Breast Cancer
Grupo Hospital de Madrid
Phase EARLY_PHASE1 Completed